Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 34
Filter
1.
Psychoneuroendocrinology ; 142: 105762, 2022 08.
Article in English | MEDLINE | ID: mdl-35679773

ABSTRACT

Major depressive disorder (MDD) and adverse childhood experiences (ACE) are associated with poor physical and mental health in adulthood. One underlying mechanism might be accelerated cellular aging. For example, both conditions, MDD and ACE, have been related to a biological marker of cellular aging, accelerated shortening of telomere length (TL). Since MDD and ACE are confounded in many studies, we aimed with the current study to further disentangle the effects of MDD and ACE on TL using a full-factorial design including four carefully diagnosed groups of healthy participants and MDD patients with and without ACE (total N = 90, all without use of antidepressants). As dependent variable, TL was assessed in leukocytes. We found no group differences based on MDD and ACE exposure in TL. While TL was negatively associated with age and male sex, TL was not associated with any measure of severity of MDD, ACE or current stress. One possible explanation for our null result may be the comparatively good physical health status of our sample. Future research is needed to elucidate the relation of TL, MDD and ACE, taking potential effect modification by medication intake and physical health status into account.


Subject(s)
Adverse Childhood Experiences , Depressive Disorder, Major , Adult , Depression , Depressive Disorder, Major/genetics , Humans , Leukocytes , Male , Telomere , Telomere Shortening
2.
Semin Arthritis Rheum ; 49(1): 43-55, 2019 08.
Article in English | MEDLINE | ID: mdl-30595409

ABSTRACT

BACKGROUND: Uveitis in juvenile idiopathic arthritis (JIAU) is frequently associated with the development of complications and visual loss. Topical corticosteroids are the first line therapy, and disease modifying anti-rheumatic drugs (DMARDs) are commonly used. However, treatment has not been standardized. METHODS: Interdisciplinary guideline were developed with representatives from the German Ophthalmological Society, Society for Paediatric Rheumatology, Professional Association of Ophthalmologists, German Society for Rheumatology, parents' group, moderated by the Association of the Scientific Medical Societies in Germany. A systematic literature analysis in MEDLINE was performed, evidence and recommendations were graded, an algorithm for anti-inflammatory treatment and final statements were discussed in a consensus meeting (Nominal Group Technique), a preliminary draft was fine-tuned and discussed thereafter by all participants (Delphi procedure). RESULTS: Consensus was reached on recommendations, including a standardized treatment strategy according to uveitis severity in the individual patient. Thus, methotrexate shall be introduced for uveitis not responding to low-dose (≤ 2 applications/day) topical corticosteroids, and a TNFalpha antibody (preferably adalimumab) used, if uveitis inactivity is not achieved. In very severe active uveitis with uveitis-related deterioration of vision, systemic corticosteroids should be considered for bridging until DMARDs take effect. If TNFalpha antibodies fail to take effect or lose effect, another biological should be selected (tocilizumab, abatacept or rituximab). De-escalation of DMARDs should be preceded by a period of  ≥ 2 years of uveitis inactivity. CONCLUSIONS: An interdisciplinary, evidence-based treatment guideline for JIAU is presented.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Antirheumatic Agents/therapeutic use , Arthritis, Juvenile/complications , Uveitis/drug therapy , Consensus , Evidence-Based Medicine , Humans , Uveitis/etiology
3.
Pathologe ; 38(6): 515-520, 2017 Nov.
Article in German | MEDLINE | ID: mdl-28993856

ABSTRACT

The eye and the ocular adnexae are rare sites for malignant non-Hodgkin lymphoma (NHL). Based on their anatomical location, intraocular lymphomas must be discerned from NHL of adnexal structures including conjunctiva, lacrimal gland, and orbit. Whereas the latter group mostly consists of indolent extranodal marginal zone B­cell lymphomas of mucosa-associated lymphoid tissue (MALT) type or secondary manifestations of systemic NHL, most primary intraocular lymphomas are classified as diffuse large B­cell lymphomas (DLBCL) and are considered a variant of primary DLBCL of the central nervous system. The most common form is primary vitreoretinal lymphoma (PVRL), which presents with nonspecific symptoms and is difficult to discern from uveitis. Diagnosis of PVRL is usually made by cytological, immunocytochemical, and molecular analysis of vitreous aspirates. Degenerative changes, limited material, and the occurrence of pseudoclonality in the molecular analysis of B­cell clonality can hamper diagnostic assessment. Novel techniques such as detection of MYD88 mutations common in PVRL can increase diagnostic sensitivity. Close cooperation with clinical colleagues and rapid specimen processing are fundamental for successful diagnosis.


Subject(s)
Eye Neoplasms/pathology , Lymphoma, B-Cell, Marginal Zone/pathology , Lymphoma, Large B-Cell, Diffuse/pathology , Humans
4.
Z Rheumatol ; 76(8): 673-681, 2017 Oct.
Article in German | MEDLINE | ID: mdl-28861674

ABSTRACT

There are many interfaces between ophthalmologists and rheumatologists. On the one hand ophthalmologists face the question if an inflammation of the eye is caused by systemic inflammatory rheumatic diseases and on the other hand rheumatologists have to consider that ocular manifestations are relatively common in some inflammatory rheumatic diseases. Furthermore, these ocular manifestations may influence therapeutic decisions of the rheumatologist. This article summarizes which ocular inflammations can be associated with rheumatoid arthritis, connective tissue diseases and vasculitides. The description of acute anterior uveitis in spondyloarthritis and in juvenile idiopathic arthritis is omitted in this article but will be dealt with elsewhere in this issue.


Subject(s)
Arthritis, Rheumatoid/diagnosis , Collagen Diseases/diagnosis , Eye Diseases/diagnosis , Vascular Diseases/diagnosis , Acute Disease , Adrenal Cortex Hormones/therapeutic use , Arthritis, Rheumatoid/drug therapy , Arthritis, Rheumatoid/epidemiology , Aspirin/therapeutic use , Collagen Diseases/drug therapy , Collagen Diseases/epidemiology , Cross-Sectional Studies , Eye Diseases/drug therapy , Eye Diseases/epidemiology , Giant Cell Arteritis/diagnosis , Giant Cell Arteritis/drug therapy , Giant Cell Arteritis/epidemiology , Humans , Immunosuppressive Agents/therapeutic use , Keratoconjunctivitis Sicca/diagnosis , Keratoconjunctivitis Sicca/drug therapy , Keratoconjunctivitis Sicca/epidemiology , Lupus Erythematosus, Systemic/diagnosis , Lupus Erythematosus, Systemic/drug therapy , Lupus Erythematosus, Systemic/epidemiology , Methotrexate/therapeutic use , Retinal Diseases/diagnosis , Retinal Diseases/drug therapy , Retinal Diseases/epidemiology , Scleritis/diagnosis , Scleritis/drug therapy , Scleritis/epidemiology , Uveitis, Anterior/diagnosis , Uveitis, Anterior/drug therapy , Uveitis, Anterior/epidemiology , Vascular Diseases/drug therapy , Vascular Diseases/epidemiology
5.
J Eur Acad Dermatol Venereol ; 31(10): 1732-1738, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28621909

ABSTRACT

BACKGROUND: In paediatric rosacea, ocular symptoms are often predominant. Literature about systemic therapy of paediatric ocular rosacea is sparse, though. OBJECTIVE: Analysis of children with ocular rosacea treated systemically, particularly addressing remission and recurrence rates. METHODS: Retrospective study reviewing the medical records of children with ocular rosacea treated with systemic antibiotic therapy. Nine of 19 patients were chosen for detailed analysis. To our knowledge, this is the first study in paediatric ocular rosacea requiring systemic therapy with a larger patient group and a longer follow-up (mean follow-up = 30.2 months). RESULTS: 17 patients (89.5%) suffered from blepharitis, 15 patients (78.9%) from conjunctivitis, twelve patients (63.2%) from chalazia/styes and nine female patients (47.4%) from corneal involvement. We used erythromycin (n = 9) or roxithromycin (n = 1) in patients younger than 8 years and doxycycline (n = 8) or minocycline (n = 1) in patients older than 8 years. Seven of nine patients treated with erythromycin, one of eight patients treated with doxycycline and the patient treated with minocycline achieved a complete remission of ocular and cutaneous symptoms. Two of nine patients treated with erythromycin, seven of eight patients treated with doxycycline and the patient treated with roxithromycin achieved a partial remission. Relapses occurred in the patient treated with minocycline (cutaneous), two of eight patients treated with doxycycline (ocular and cutaneous) and one of nine patients treated with erythromycin (cutaneous). CONCLUSION: To achieve a complete remission of cutaneous and ocular rosacea, a long-term anti-inflammatory treatment of at least 6 months is necessary. The relapse rates seem to be lower than in adults especially in the patients treated with erythromycin.


Subject(s)
Doxycycline/therapeutic use , Erythromycin/therapeutic use , Minocycline/therapeutic use , Rosacea/drug therapy , Roxithromycin/therapeutic use , Adolescent , Child , Child, Preschool , Eye Diseases/drug therapy , Female , Humans , Infant , Male , Recurrence , Remission Induction , Retrospective Studies , Skin Diseases/drug therapy
6.
Ophthalmologe ; 112(3): 217-22, 2015 Mar.
Article in German | MEDLINE | ID: mdl-25693876

ABSTRACT

Choroidal lymphoma is a rare disease and can be classified into primary and secondary choroidal lymphomas. Primary choroidal lymphoma is a low-grade extranodal marginal zone B-cell lymphoma and secondary choroidal lymphomas present ocular manifestations of disseminated systemic lymphomas. Typical clinical features of choroidal lymphoma are multifocal, yellow-whitish choroidal infiltrates. The vitreous body is usually clear and cell-free. Choroidal lymphoma has a tendency to extend through the sclera. In contrast to primary choroidal lymphoma, which is more often unilateral, does not show signs of anterior segment involvement and has a slow progression, secondary choroidal lymphoma is more often bilateral, has a rapidly progressive course with anterior segment and vitreous involvement and belongs to the high-grade lymphomas. The definitive diagnosis of choroidal lymphoma can only be confirmed by histopathological examination of biopsy tissue. The choroidal biopsy is the gold standard in the diagnostics of choroidal lymphoma. To date, no standardized treatment for choroidal lymphoma has been established. The treatment modalities include external beam radiotherapy, immunotherapy with rituximab and chemotherapy. The prognosis for survival of primary choroidal lymphoma is usually good. The prognosis of secondary choroidal lymphoma depends on the malignancy grade of systemic lymphoma.


Subject(s)
Choroid Neoplasms/diagnosis , Choroid Neoplasms/therapy , Lymphoma/diagnosis , Lymphoma/therapy , Radiotherapy, Conformal/methods , Antineoplastic Agents/therapeutic use , Chemoradiotherapy/methods , Diagnosis, Differential , Humans , Immunotherapy/methods
7.
Ophthalmologe ; 111(12): 1219-32; quiz 1233-4, 2014 Dec.
Article in German | MEDLINE | ID: mdl-25448321

ABSTRACT

Intermediate uveitis is a form of intraocular inflammation in which the vitreous body is the major site of inflammation. Intermediate uveitis is primarily treated medicinally and systemic corticosteroids are the mainstay of therapy. When recurrence of uveitis or side effects occur during corticosteroid therapy an immunosuppressive treatment is required. Cyclosporine A is the only immunosuppressive agent that is approved for therapy of uveitis in Germany; however, other immunosuppressive drugs have also been shown to be effective and well-tolerated in patients with intermediate uveitis. In severe therapy-refractory cases when conventional immunosuppressive therapy has failed, biologics can be used. In patients with unilateral uveitis or when the systemic therapy is contraindicated because of side effects, an intravitreal steroid treatment can be carried out. In certain cases a vitrectomy may be used.


Subject(s)
Adrenal Cortex Hormones/administration & dosage , Cyclosporine/administration & dosage , Immunosuppressive Agents/administration & dosage , Uveitis/diagnosis , Uveitis/therapy , Combined Modality Therapy/methods , Evidence-Based Medicine , Humans , Intravitreal Injections , Treatment Outcome
10.
Graefes Arch Clin Exp Ophthalmol ; 252(1): 117-24, 2014 Jan.
Article in English | MEDLINE | ID: mdl-24287937

ABSTRACT

BACKGROUND: To assess the short-term and long-term efficacy of oral therapy with valganciclovir in patients with Posner-Schlossman Syndrome (PSS). METHODS: This is a retrospective observational study on 11 patients with PSS treated with valganciclovir. The PSS was diagnosed clinically on the basis of recurrent episodes of anterior uveitis associated with attacks of elevated intraocular pressure (IOP). All patients who did not respond to aciclovir, or whose cytomegalovirus (CMV) DNA polymerase chain reaction (PCR) analysis of the aqueous humour was positive, were treated with valganciclovir (Valcyte®). Initially, the drug was given 900 mg twice daily for 3 weeks, followed by 450 mg twice daily for a mean period of 20 months (range 10-46 months). RESULTS: Eleven patients with mean age of 44 years were included in this study. Four of 11 patients were working in a sanitary profession. Before initiation of valgancicloivir therapy, the highest IOP was 68 mmHg (mean 45 mmHg ±9 mmHg). In the first week of treatment, the IOP decreased significantly (mean 16 mmHg ±10 mmHg) and maintained stability during the entire treatment period. In seven of 11 (63.6 %) patients, valganciclovir led to resolution of inflammatory activity and stable IOP. In six patients, the therapy could be discontinued after a mean of 14 months. However, two patients had a recurrence after discontinuation of valganciclovir treatment. No side effects of therapy were observed. CONCLUSIONS: Long-term oral therapy with valganciclovir seems to lower the recurrence rate in patients with clinically diagnosed PSS.


Subject(s)
Antiviral Agents/therapeutic use , Cytomegalovirus Infections/drug therapy , Eye Infections, Viral/drug therapy , Ganciclovir/analogs & derivatives , Ocular Hypertension/drug therapy , Uveitis, Anterior/drug therapy , Administration, Oral , Adult , Antihypertensive Agents/therapeutic use , Aqueous Humor/virology , Cytomegalovirus/genetics , Cytomegalovirus/isolation & purification , Cytomegalovirus Infections/diagnosis , Cytomegalovirus Infections/virology , DNA, Viral/analysis , Eye Infections, Viral/diagnosis , Eye Infections, Viral/virology , Female , Follow-Up Studies , Ganciclovir/therapeutic use , Humans , Intraocular Pressure , Male , Middle Aged , Ocular Hypertension/diagnosis , Ocular Hypertension/virology , Polymerase Chain Reaction , Retrospective Studies , Syndrome , Treatment Outcome , Uveitis, Anterior/diagnosis , Uveitis, Anterior/virology , Valganciclovir
11.
Z Rheumatol ; 71(8): 685-96; quiz 697, 2012 Oct.
Article in German | MEDLINE | ID: mdl-23052559

ABSTRACT

Behçet's disease is a systemic disorder with the histopathological correlate of leukocytoclastic vasculitis. Pathogenetically, besides a strong genetic component participation of the innate immune system and an autoinflammatory component are discussed. The disease is most common in countries along the former silk route but in Germany the disease is rare (prevalence approximately 0.6/100,000). Oral aphthous ulcers are the main symptom, followed by skin manifestations, genital ulcers and oligoarthritis of large joints. Severe manifestations, threatening quality of life and even life itself, are the gastrointestinal manifestations which often perforate, arterial, mainly pulmonary arterial aneurysms which cause life-threatening bleeding, CNS manifestations and ocular disease, which with occlusive retinal vasculitis often leads to blindness. For milder manifestations low-dose steroids and colchicine are used, for moderate manifestations such as arthritis or ocular disease not immediately threatening visual acuity, azathioprin or cyclosporin A are combined with steroids. For severe manifestations, interferon-alpha, TNF-antagonists or cytotoxic drugs are recommended. Interleukin 1 (IL-1) antagonists are currently being examined in clinical studies.


Subject(s)
Behcet Syndrome/drug therapy , Behcet Syndrome/therapy , Cyclosporine/therapeutic use , Immunosuppressive Agents/therapeutic use , Steroids/therapeutic use , Humans
12.
Ophthalmologe ; 109(6): 548-57, 2012 Jun.
Article in German | MEDLINE | ID: mdl-22699945

ABSTRACT

Behcet's disease is a multisystem disorder with the histopathological correlate of leukocytoclastic vasculitis. The classification criteria for the disease include the presence of recurrent oral aphthous ulcers combined with at least two other manifestations, such as genital aphthous ulcers, skin manifestations (mostly erythema nodosa or pseudofolliculitis) and ocular manifestations (panuveitis or posterior uveitis with retinal vasculitis). A positive pathergy test is regarded as pathognomonic for the disease and a sterile papulopustule occurs after a sterile needle prick of the forearm. However, this test is positive in only 15% of the patients. The prognosis of Behcet's disease becomes unfavorable when vital organs are involved. This is the case for involvement of the central nervous system which occurs in 10% of patients, arterial and pulmonary arterial aneurysms and gastrointestinal involvement, which clinically and histopathologically is difficult to differentiate from inflammatory bowel disease but tends to perforate. Oligoarthritis, which occurs in approximately 50% of the patients, causes problems concerning the differential diagnosis from classical forms of spondyloarthritis. Behcet's disease is associated with HLA-B51 in 50-80% of the cases depending on the country of origin of the patient. The prognosis becomes unfavorable if the disease manifests in young male patients. The treatment of extraocular manifestations depends on the aggressiveness. Milder manifestations are treated with low dose prednisolone and steroid sparing immunosuppressants, such as azathioprine or cyclosporine A. In cases with more severe manifestations, such as central nervous system (CNS) involvement cyclophosphamide or TNF antagonists and in selected cases also interferon alpha can be considered.


Subject(s)
Arthritis/diagnosis , Arthritis/therapy , Behcet Syndrome/diagnosis , Behcet Syndrome/therapy , Vasculitis, Leukocytoclastic, Cutaneous/diagnosis , Vasculitis, Leukocytoclastic, Cutaneous/therapy , Humans , Male
13.
Ophthalmologe ; 109(6): 568-74, 2012 Jun.
Article in German | MEDLINE | ID: mdl-22699948

ABSTRACT

Uveitis due to Behçet's disease belongs to those types of intraocular inflammation with a poor visual prognosis. Despite early treatment with corticosteroids and immunosuppressants, patients often become blind. With the so-called biologicals, highly effective drugs are now available which very rapidly lead to quiescence of intraocular inflammation and which successfully avoid further uveitis relapse. Recently, an interdisciplinary group of experts on behalf of the EULAR developed nine recommendations for the treatment of Behçet's disease. Two of these address ocular involvement. Compared with TNF alpha antagonists, interferon alpha offers the advantage that even after cessation of treatment a high percentage of patients remain in remission. This article provides an overview on current medical treatment of ocular Behçet's disease.


Subject(s)
Behcet Syndrome/diagnosis , Behcet Syndrome/drug therapy , Biological Products/therapeutic use , Blindness/prevention & control , Immunosuppressive Agents/therapeutic use , Humans
14.
Rheumatol Int ; 32(5): 1121-33, 2012 May.
Article in English | MEDLINE | ID: mdl-22083610

ABSTRACT

Uveitis in juvenile idiopathic arthritis (JIA) is frequently associated with the development of complications and visual loss. Topical corticosteroids are the first-choice therapy, and immunosuppression is commonly used. However, treatment has not been standardized. Representatives from the German Ophthalmological Society, Society for Childhood and Adolescent Rheumatology, and the German Society for Rheumatology reached consensus on a standardized treatment strategy according to disease severity in the individual patient. The recommendations were based on a systematic literature analysis in MEDLINE and consensus expert meetings. Evidence and recommendations were graded, and an algorithm for anti-inflammatory treatment and final statements confirmed in a Delphi method. An interdisciplinary, evidence-based treatment guideline for JIA uveitis is presented.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Arthritis, Juvenile/complications , Evidence-Based Medicine/standards , Ophthalmology/standards , Rheumatology/standards , Uveitis/drug therapy , Adolescent , Algorithms , Anti-Inflammatory Agents/adverse effects , Arthritis, Juvenile/immunology , Child , Cooperative Behavior , Delphi Technique , Germany , Humans , Interdisciplinary Communication , Patient Care Team , Recurrence , Treatment Outcome , Uveitis/diagnosis , Uveitis/etiology , Uveitis/immunology
15.
Klin Monbl Augenheilkd ; 228(10): 900-4, 2011 Oct.
Article in German | MEDLINE | ID: mdl-21656461

ABSTRACT

BACKGROUND: Behçet's disease is a systemic vasculitis disorder of unknown aetiology. Ocular involvement, especially with vasculitis, is detected in up to 80 % of the cases. Anterior segment involvement such as cataract is also seen in the follow-up of patients who are then treated surgically. In this study, we aimed to analyze the outcomes of cataract surgery in patients with Behçet's disease retrospectively. PATIENTS AND METHODS: The records of 9 patients (12 eyes) with Behçet's disease who underwent phacoemulsification with IOL implantation in 11 eyes and extracapsular cataract extraction (ECCE) with IOL implantation in one eye between June 2001 and September 2009 were evaluated retrospectively. The visual outcome and complications were analysed. RESULTS: The mean follow-up was 33.8 months (range 3 to 88 months). The mean preoperative LogMAR BCVA was 1.15 ± 0.53 (95 % CI: 0.81 - 1.49) and increased to 0.36 ± 0.32 (95 % CI: 0.15 - 0.56) at last medical visit (p < 0.001). The most frequent postoperative complication was posterior capsular opacification, which developed in 2 eyes (17 %). Other complications were mild fibrinous reaction in 1 eye (8 %). CONCLUSIONS: The outcomes of cataract surgery in patients with Behçet's disease were satisfactory. The great majority of the patients regained and retained a good visual outcome and had fewer postoperative complications.


Subject(s)
Behcet Syndrome/surgery , Lenses, Intraocular , Adult , Anti-Inflammatory Agents/administration & dosage , Azathioprine/administration & dosage , Cataract Extraction/methods , Female , Humans , Immunosuppressive Agents/administration & dosage , Interferon alpha-2 , Interferon-alpha/administration & dosage , Male , Middle Aged , Perioperative Care , Postoperative Complications/etiology , Prednisolone/administration & dosage , Recombinant Proteins/administration & dosage , Retrospective Studies , Young Adult
16.
Ophthalmologe ; 108(3): 204-12, 2011 Mar.
Article in German | MEDLINE | ID: mdl-21350868

ABSTRACT

Interferon alpha (IFN-α) and interferon beta (IFN-ß) are naturally occurring cytokines, which belong to the type I interferons and share the same receptor leading to very similar therapeutic effects. The immunomodulatory effect of type I interferons includes modulation of antibody production, inhibition of lymphocyte proliferation, inhibition of delayed-type hypersensitivity and enhancement of T-cell and NK-cell cytotoxicity. An increasing number of open clinical studies and case reports have demonstrated the efficacy of IFN-α for severe ocular inflammation in patients with Behçet's disease and of interferon-ß, which has been used mainly for the treatment of multiple sclerosis.


Subject(s)
Eye Diseases/drug therapy , Interferon-alpha/adverse effects , Interferon-alpha/therapeutic use , Interferon-beta/therapeutic use , Animals , Antibody Formation/drug effects , Antibody Formation/immunology , Behcet Syndrome/drug therapy , Behcet Syndrome/immunology , Cytotoxicity, Immunologic/drug effects , Cytotoxicity, Immunologic/immunology , Dose-Response Relationship, Drug , Eye Diseases/immunology , Follow-Up Studies , Humans , Hypersensitivity, Delayed/drug therapy , Hypersensitivity, Delayed/immunology , Interferon-beta/adverse effects , Lymphocyte Activation/drug effects , Lymphocyte Activation/immunology , Macular Edema/drug therapy , Macular Edema/immunology , Multiple Sclerosis/drug therapy , Multiple Sclerosis/immunology , Retinal Vasculitis/drug therapy , Retinal Vasculitis/immunology , Uveitis/drug therapy , Uveitis/immunology
17.
Ophthalmologe ; 107(7): 672-5, 2010 Jul.
Article in German | MEDLINE | ID: mdl-20571806

ABSTRACT

To date cyclosporine is the only immunosuppressive drug approved for the treatment of uveitis in Germany. However, side effects often limit its use in daily practice. Voclosporin (Luveniq) represents a next generation calcineurin inhibitor which had shown efficacy in an animal model of experimental autoimmune uveitis as well as in clinical trials for the prevention of renal allograft rejection and for plaque psoriasis. The LUMINATE program included three prospective, randomized, double-masked, placebo-controlled multicenter trials which demonstrated the efficacy and tolerability of voclosporin 0.4 mg/kg b.i.d. in noninfectious intermediate and posterior uveitis and panuveitis. In Europe, the Marketing Approval Application (MAA) of voclosporin for the treatment of uveitis was submitted to the European Medicines Agency (EMA) in February 2010 and could be approved in March 2011.


Subject(s)
Cyclosporine/administration & dosage , Uveitis/drug therapy , Humans , Immunosuppressive Agents/administration & dosage , Injections, Intra-Arterial , Randomized Controlled Trials as Topic , Treatment Outcome , Uveitis/diagnosis
18.
Z Rheumatol ; 69(5): 419-24, 2010 Jul.
Article in German | MEDLINE | ID: mdl-20517612

ABSTRACT

Connective tissue diseases and systemic vasculitides are commonly associated with ocular manifestations, which can lead to severe complications and even blindness. The present review article describes these ocular manifestations, their signs and symptoms and possible treatment options for Sjoegren's syndrome, systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APLS), as well as those of giant cell arteritis/cranial arteritis, ANCA-associated vasculitides and Behçet's disease. Additionally, possible ocular adverse effects of antimalarial agents are described.


Subject(s)
Connective Tissue Diseases/diagnosis , Eye Diseases/diagnosis , Vasculitis/diagnosis , Adrenal Cortex Hormones/administration & dosage , Adrenal Cortex Hormones/adverse effects , Biological Products/administration & dosage , Biological Products/adverse effects , Blindness/etiology , Blindness/prevention & control , Connective Tissue Diseases/drug therapy , Diagnosis, Differential , Dose-Response Relationship, Drug , Drug Administration Schedule , Drug Therapy, Combination , Eye Diseases/drug therapy , Humans , Immunosuppressive Agents/administration & dosage , Immunosuppressive Agents/adverse effects , Long-Term Care , Prednisolone/administration & dosage , Prednisolone/adverse effects , Vasculitis/drug therapy
19.
Ophthalmologe ; 107(5): 427-34, 2010 May.
Article in German | MEDLINE | ID: mdl-20393734

ABSTRACT

Secondary glaucoma represents a frequent complication especially in chronic forms of uveitis. Different immunological and mechanical alterations can be responsible for the elevation of intraocular pressure (IOP). To enable a tailored treatment strategy the diagnostic process has to include the search for characteristic findings which can be indicative for the underlying uveitis entity. Sometimes it can be difficult to distinguish inflammatory glaucoma from primary non-inflammatory forms of glaucoma as well as from steroid-induced elevation of IOP. Treatment of secondary glaucoma due to uveitis has to include not only medicinal and surgical lowering of IOP but also control of the inflammation, e.g. by immunosuppressive or antiviral drugs. Under normal conditions, beta-receptor antagonists and carbonic anhydrase inhibitors will represent first-line topical treatment. Besides cyclodestructive and filtrating procedures, the use of drainage implants has gained importance in the surgical treatment of secondary glaucoma due to intraocular inflammation.


Subject(s)
Glaucoma/diagnosis , Glaucoma/etiology , Uveitis/complications , Uveitis/diagnosis , Glaucoma/surgery , Humans , Uveitis/therapy
20.
Ophthalmologe ; 106(12): 1121-5, 2009 Dec.
Article in German | MEDLINE | ID: mdl-19499227

ABSTRACT

BACKGROUND: Arthrogryposis multiplex congenita (AMC) is a heterogeneous pattern of symptoms consisting of clinically different types. AMC is a non-progressive condition, which is characterized by congenital contracture of several joints in different body areas and may also occur as a manifestation of other syndromes. In such syndromes retinopathy as an ophthalmological manifestation of AMC has been described in the literature in only two patients. CASE REPORT: A 12-year-old girl with AMC presented with progressive visual loss since 1 year. Visual acuity was 0.5 in the right and 0.8 in the left eye. Visual fields were concentrically constricted. Funduscopy revealed an atrophic retinal pigment epithelium of the whole fundus with vital optic discs. In the scotopic electroretinogram (ERG) amplitudes were dramatically decreased or absent and cone signals were delayed. The multifocal ERG (mfERG) presented pathologically reduced amplitudes in the macular region as well as in the periphery. Examinations 5 and 8 years later revealed a reduction of visual acuity to 0.05 in the right and to 0.1 in the left eye, in addition the results of perimetry and of the Ganzfeld-ERG had deceased and the mfERG was no longer measurable. CONCLUSION: This young female demonstrated an AMC in combination with retinitis pigmentosa, but other disease manifestations or cerebral retardation could not be found. We present here an unusual case of what seems to be a new athrogryposis syndrome.


Subject(s)
Arthrogryposis/diagnosis , Retinitis Pigmentosa/diagnosis , Child , Female , Humans , Syndrome
SELECTION OF CITATIONS
SEARCH DETAIL
...